Institute for Pathology, Hannover Medical School, 30625 Hannover, Germany.
German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), 30625 Hannover, Germany.
Cells. 2021 Jun 1;10(6):1362. doi: 10.3390/cells10061362.
Pulmonary fibroelastotic remodelling occurs within a broad spectrum of diseases with vastly divergent outcomes. So far, no comprehensive terminology has been established to adequately address and distinguish histomorphological and clinical entities. We aimed to describe the range of fibroelastotic changes and define stringent histological criteria. Furthermore, we wanted to clarify the corresponding terminology in order to distinguish clinically relevant variants of pulmonary fibroelastotic remodelling. We revisited pulmonary specimens with fibroelastotic remodelling sampled during the last ten years at a large European lung transplant centre. Consensus-based definitions of specific variants of fibroelastotic changes were developed on the basis of well-defined cases and applied. Systematic evaluation was performed in a steps-wise algorithm, first identifying the fulcrum of the respective lesions, and then assessing the morphological changes, their distribution and the features of the adjacent parenchyma. We defined typical alveolar fibro-elastosis as collagenous effacement of the alveolar spaces with accompanying hyper-elastosis of the remodelled and paucicellular alveolar walls, independent of the underlying disease in 45 cases. Clinically, this pattern could be seen in (idiopathic) pleuroparenchymal fibro-elastosis, interstitial lung disease with concomitant alveolar fibro-elastosis, following hematopoietic stem cell and lung transplantation, autoimmune disease, radio-/chemotherapy, and pulmonary apical caps. Novel in-transit and activity stages of fibroelastotic remodelling were identified. For the first time, we present a comprehensive definition of fibroelastotic remodelling, its anatomic distribution, and clinical associations, thereby providing a basis for stringent patient stratification and prediction of outcome.
肺纤维弹性组织重构发生在具有广泛差异结局的多种疾病中。迄今为止,尚未建立全面的术语来充分解决和区分组织形态学和临床实体。我们旨在描述纤维弹性改变的范围,并定义严格的组织学标准。此外,我们希望澄清相关术语,以便区分具有临床意义的肺纤维弹性组织重构变体。我们重新研究了过去十年在一个大型欧洲肺移植中心采集的具有纤维弹性重构的肺标本。在明确界定的病例基础上,制定了特定纤维弹性变化变体的共识定义,并加以应用。通过逐步算法进行系统评估,首先确定病变的枢轴,然后评估形态变化、其分布以及相邻实质的特征。我们在 45 例患者中定义了典型的肺泡纤维弹性化,即肺泡空间的胶原性消失,伴有重构和细胞稀少的肺泡壁的过度弹性化,与基础疾病无关。临床上,这种模式可见于(特发性)胸膜肺纤维弹性化、伴有肺泡纤维弹性化的间质性肺疾病、造血干细胞和肺移植后、自身免疫性疾病、放射/化学疗法以及肺尖帽。确定了纤维弹性组织重构的新型过境和活动阶段。这是我们首次全面定义纤维弹性组织重构、其解剖分布和临床关联,从而为严格的患者分层和预后预测提供了基础。